This trial will test whether siltuximab can lessen the severity of CRS and ICANS in patients receiving CAR T-cell therapy for blood cancer.
- Cytokine Release Syndrome
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Cytokine Storm
- Cytokine Release Syndrome (CRS)
- Non-Hodgkin Lymphoma
1 Primary · 3 Secondary · Reporting Duration: Baseline through day 90
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Siltuximab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the estimated number of participants included in this research?
"Confirmed. According to the records on clinicaltrials.gov, this trial is actively searching for 30 enrollees at 1 medical centre - with its first posting date being November 15th 2021 and its final edit occurring two days later." - Anonymous Online Contributor
What prior experiments have explored the efficacy of Siltuximab?
"Currently, 4 different trials are observing the effects of siltuximab. Not one is in its final phase 3; however there are 6 sites across New York City that have started testing this medication's efficacy." - Anonymous Online Contributor
Does this clinical trial currently have openings for participants?
"Affirmative. The clinical trial data hosted on clinicialtrials.gov verifies that this experiment commenced recruitment as of November 15th 2021 and was most recently revised on the 17th of November 2021. Currently, 30 individuals are needed for participation at a single medical site." - Anonymous Online Contributor
What evidence exists for the safety of Siltuximab in humans?
"Our team has determined that siltuximab's safety score is a 2, as the drug is currently in its second phase of clinical trials and there are data points that suggest it can be safe but none to support its effectiveness." - Anonymous Online Contributor